Anzeige
Mehr »
Login
Dienstag, 08.04.2025 Börsentäglich über 12.000 News von 689 internationalen Medien
Gold trotzt dem Börsencrash - dieser Explorer überzeugt!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1JCLB | ISIN: FR0011049824 | Ticker-Symbol: 4ZG
Frankfurt
08.04.25
08:14 Uhr
2,595 Euro
+0,140
+5,70 %
Branche
Software
Aktienmarkt
Sonstige
1-Jahres-Chart
MEDIAN TECHNOLOGIES Chart 1 Jahr
5-Tage-Chart
MEDIAN TECHNOLOGIES 5-Tage-Chart
RealtimeGeldBriefZeit
2,6652,75519:10

Aktuelle News zur MEDIAN TECHNOLOGIES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MEDIAN TECHNOLOGIES Aktie jetzt für 0€ handeln
MoMedian Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of March 31, 2025 119Pursuant to article L-223-8 II of the French "code de Commerce" and 223-16 of the AMF's General Regulations. Regulatory News: Median Technologies (Paris:ALMDT): Total number of shares ...
► Artikel lesen
31.03.eyonis LCS, Median Technologies' AI-Powered Software as a Medical Device for Lung Cancer Screening, Confirmed Efficacy and Safety in RELIVE Pivotal Study211All secondary endpoints required to support eyonis LCS' intended use and desired marketing claims achieved in RELIVE eyonis LCS previously met primary endpoint, achieving statistically...
► Artikel lesen
07.03.Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of February 28, 2025306Pursuant to article L-223-8 II of the French "code de Commerce" and 223-16 of the AMF's General Regulations. Regulatory News: Median Technologies (Paris:ALMDT): Total number of shares ...
► Artikel lesen
03.03.Median Technologies Announces the Availability of the Preparatory Documents for the Shareholders' Extraordinary General Meeting on March 20, 2025228Regulatory News: The shareholders of Median Technologies (FR0011049824, ALMDT, PEA/PME scheme eligible, "Median" or "The Company") are invited to participate in the Shareholders' Extraordinary...
► Artikel lesen
26.02.Median Technologies to Present at TD Cowen's 45th Annual Health Care Conference232Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA/SME eligible, "Median" or "The Company"), a leading developer of eyonis, a suite of artificial intelligence (AI) powered Software...
► Artikel lesen
24.02.Median Technologies to Showcase Its Artificial Intelligence Software as a Medical Device for Lung Cancer Screening, eyonis LCS, at the European Congress of Radiology236Industry presentation at the AI Theatre: "eyonis LCS: Pioneering AI/ML Software as a Medical Device Redefining the Future of Lung Cancer Screening Median eyonis teams will be at booth AI-18...
► Artikel lesen
11.02.Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of January 31st, 2025250Pursuant to article L-223-8 II of the French "code de Commerce" and 223-16 of the AMF's General Regulations. Regulatory News: Median Technologies (Paris:ALMDT): Total number of shares...
► Artikel lesen
05.02.Median Technologies Gives Update on Drawdowns of the Iris Equity Line276Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA/SME scheme eligible), a leading developer of eyonis, a suite of artificial intelligence (AI) powered Software as a Medical Device...
► Artikel lesen
03.02.Median Technologies: eyonis Lung Cancer Screening (LCS) Meets Primary Endpoint in RELIVE Clinical Trial, the Final Pivotal Study Required for Regulatory Submissions271Primary endpoint met with statistical significance (p=0.027) in pivotal RELIVE trial of eyonis LCS, Median's AI/ML-based Software as a Medical Device for lung cancer screening eyonis LCS...
► Artikel lesen
31.01.Median Technologies Reports 2024 Key Financial Indicators and 2025 Outlook341H2 2024 revenue €12.0 million up 10.2% compared to H2 2023 FY 2024 revenue €22.9 million up 3.3% compared to 2023 Growing order backlog at €71.0 million, as of December 31, 2024...
► Artikel lesen
24.01.Median Technologies securing up to €47.5 million to support AI lung cancer diagnostic eyonis regulatory filings and commercialization in U.S. and EU395Repayment of 2020 EIB loan to be rescheduled to October 2025 from April New €37.5 million 2025 EIB loan under appraisal, final authorization stage New up to €10 million equity line...
► Artikel lesen
14.01.Median Technologies: Financial Communications Schedule for the First Half of 2025423Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible), announces the publication date for its 2024 results: Publication Date ...
► Artikel lesen
09.01.Half Year Median Technologies Liquidity Contract Statement290Regulatory News: Under the liquidity contract entrusted by Median Technologies (FR0011049824, ALMDT, PEA/SME eligible, "Median" or "the Company") to TP ICAP (Europe), the following resources were...
► Artikel lesen
08.01.Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of December 31st, 2024214Pursuant to article L-223-8 II of the French "code de Commerce" and 223-16 of the AMF's General Regulations. Regulatory News: Median Technologies (Paris:ALMDT): Total number of shares...
► Artikel lesen
11.12.24Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of November 30th, 2024316Pursuant to article L-223-8 II of the French "code de Commerce" and 223-16 of the AMF's General Regulations. Regulatory News: Median Technologies (Paris:ALMDT): Total number of shares...
► Artikel lesen
26.11.24Median Technologies to Showcase AI-Powered Lung Cancer Diagnostic eyonis LCS at the Radiological Society of North America (RSNA) 202495Peer-reviewed scientific e-poster: "Performances of an End-to-End AI/ML CADe/CADx SaMD for Nodule Detection and Characterization in Lung Cancer Screening on an Independent Cohort Compared to Radiologists."...
► Artikel lesen
12.11.24Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of October 31st, 2024313Pursuant to article L-223-8 II of the French "code de Commerce" and 223-16 of the AMF's General Regulations. Regulatory News: Median Technologies (Paris:ALMDT): Total number of shares...
► Artikel lesen
07.11.24Median Technologies Hosted Insightful Key Opinion Leader (KOL) Webinar on eyonis Lung Cancer Screening (LCS) REALITY Data413Two globally leading pulmonologists reviewed REALITY data, AI and the potential impact on lung cancer screening Replay in English is available on the link here A French subtitled...
► Artikel lesen
30.10.24Median Technologies to Host Key Opinion Leader (KOL) Webinar on AI and Lung Cancer Screening335Webinar to focus on the eyonis Lung Cancer Screening (LCS) REALITY data November 7, 2024 1:30 pm CET 7:30 am ET Registration link Regulatory News: Median Technologies (FR0011049824, ALMDT...
► Artikel lesen
24.10.24Median Technologies Reports 2024 Q3 Operational and Financial Update and 2024 Half-Year Results386eyonis LCS pivotal REALITY study met all primary and secondary endpoints A webcast including Key Opinion Leaders will be held on November 7, 2024, to discuss the REALITY study results ...
► Artikel lesen
Seite:  Weiter >>
39 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1